Who are oral antipsychotic medication's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Barhemsys, Vraylar, Rexulti, Aristada, Lonasen, Neupro.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-antipsychotic-medication.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

oral antipsychotic medication — Competitive Intelligence Brief

oral antipsychotic medication (oral antipsychotic medication) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: oral antipsychotic. Area: Psychiatry.

phase 3 oral antipsychotic Dopamine receptor Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

oral antipsychotic medication (oral antipsychotic medication) — US Department of Veterans Affairs. Blocks dopamine receptors in the brain to help manage psychosis symptoms.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
oral antipsychotic medication TARGET	oral antipsychotic medication	US Department of Veterans Affairs	phase 3	oral antipsychotic	Dopamine receptor
Barhemsys	AMISULPRIDE	Acacia	marketed	Dopamine-2 Receptor Antagonist [EPC]	D(2) dopamine receptor	2020-01-01
Vraylar	CARIPRAZINE	AbbVie	marketed	Atypical Antipsychotic [EPC]	D(3) dopamine receptor	2015-01-01
Rexulti	BREXPIPRAZOLE	Otsuka	marketed	Atypical Antipsychotic [EPC]	D(2) dopamine receptor	2015-01-01
Aristada	ARIPIPRAZOLE LAUROXIL	Alkermes Inc	marketed		D(2) dopamine receptor	2015-01-01
Lonasen	BLONANSERIN	Dainippon Sumitomo Pharma Co., Ltd.	marketed	blonanserin	D(2) dopamine receptor	2008-01-01
Neupro	ROTIGOTINE	UCB	marketed	Nonergot Dopamine Agonist [EPC]	dopamine receptors	2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (oral antipsychotic class)

US Department of Veterans Affairs · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oral antipsychotic medication — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-antipsychotic-medication. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab